3-Methoxyphenylacetyl chloride → N-[5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-2-(3-methoxyphenyl)acetamide
반응식
[CH:1]1([O:7][C:8]2[N:13]3[N:14]=[C:15]([NH2:17])[N:16]=[C:12]3[CH:11]=[CH:10][CH:9]=2)[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.[CH3:18][O:19][C:20]1[CH:21]=[C:22]([CH2:26][C:27](Cl)=[O:28])[CH:23]=[CH:24][CH:25]=1>>[CH:1]1([O:7][C:8]2[N:13]3[N:14]=[C:15]([NH:17][C:27](=[O:28])[CH2:26][C:22]4[CH:23]=[CH:24][CH:25]=[C:20]([O:19][CH3:18])[CH:21]=4)[N:16]=[C:12]3[CH:11]=[CH:10][CH:9]=2)[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6]1참가 물질
3
실험 절차
The title compound was prepared following procedure and work up described for intermediate B1 but starting from 5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyridin-2-amine ((A11), 80 mg; 0.34 mmol; 1.0 eq.) and 3-methoxyphenylacetyl chloride (64 μl; 0.41 mmol; 1.2 eq.) as a white powder (11 mg, 8%). HPLC, Rt: 3.60 min. (purity 88.2%). LC/MS, M+(ESI): 381.1, M−(ESI): 379.1.
출처 및 근거
- ORD 기록
- ord-1000977d9afb4ef390e0cee751870d3f
- 출처 데이터셋
- uspto-grants-2012_09